Octagon Research Solutions, Inc. Introduces Its Electronic Data Capture Blog Discussion Forum
CEO Chairman Jim Walker of Octagon Research Solutions, Inc., a provider of software and services to the life sciences industry, announced today that a new Electronic Data Capture (EDC) Blog entitled, ?EDC Connections? Discussion Forum is now available on the Octagon Research Solutions, Inc. website.
Octagon Research Solutions, Inc. Introduces Its Electronic Data Capture Blog Discussion Forum
(WAYNE, PA, July 30, 2008) — CEO Chairman Jim Walker of Octagon Research Solutions, Inc., a provider of software and services to the life sciences industry, today announced that a new Electronic Data Capture (EDC) Blog entitled, “EDC Connections ” Discussion Forum is now available on the Octagon Research Solutions, Inc. website. This Blog Discussion Forum will be authored and hosted by Dan Crawford, director, Clinical Data Strategies and Dawn Kaminski, consultant, Clinical Data Strategies.
The EDC Connections Blog and EDC Discussion Forum were developed as a mechanism for promoting communication across the industry. They will provide a forum for industry colleagues to share ideas, opinions and best practices relating to EDC. This new forum and blog evolved as a natural complement to Octagon’s successful Regulatory Blog entitled, “Regulatory Matters,” and the popular eCTD Discussion Forum.
“Clients are getting information from many different sources,” notes Mr. Crawford. “We felt the need to increase the dialog, share our thoughts on the topic and encourage discussion in a way that is easy (and sometimes entertaining) for our colleagues in industry.” Ms. Kaminski adds, “We are seeing many people register for both the eCTD and the EDC forums because the industry is beginning to comprehend and look for efficiencies within the many process connections from data capture to submission.”
Dan Crawford has over 20 years of professional experience in the life sciences industry. In his current role at Octagon, he provides consulting and training in regard to the implementation of Clinical Data Interchange Standard Consortium (CDISC) Study Data Tabulation Model (SDTM) standards within the clinical data lifecycle. Prior to Octagon, he spent four years as the Director of Clinical Data Management for a major Contract Research Organization (CRO) where he oversaw the Data Management department.
Dawn Kaminski has over 10 years of industry experience. She has held various positions during that time including Project Manager and Director of Data Management. In her most recent position for a major CRO she was the primary consultant to both internal and external clients on data management issues. At Octagon, she performs assessments on electronic clinical data in order to determine compliance and provides guidance in ensuring that the clinical trial output is compliant with SDTM and eSubmission standards.
As a team, Dan and Dawn have helped many clients prepare for clinical data standards and the implementation of EDC. They have been instrumental in the development and enhancement of ViewPoint® FUSE, Octagon's integrated EDC software platform that is comprised of a series of pre-qualified and reusable study modules that are configured specifically for each protocol.
“Dan and Dawn have quite a following in industry,” noted Kirk Gallion, president, Octagon Research Solutions, Inc. “Their expertise and knowledge of clinical data processes has helped many clients and has been critical to the successful launch of ViewPoint FUSE. The Blog and Discussion Forum will be a valuable resource for anyone responsible for managing electronic clinical data.”
For more information about Octagon and its’ EDC people, process and technology, you may contact us at 610-535-6500 or visit our website at www.octagonresearch.com
About Octagon Research Solutions, Inc.
Octagon is a pioneer and leading provider of breakthrough software and services to the life sciences industry. Octagon’s eCTD and CDISC solutions provide the people, process and technology required to optimize drug development from data collection to submission. Our regulatory, clinical, process and software offerings provide a unique combination of deep domain knowledge, cross-functional electronic submission expertise, a holistic process approach, and integrated solutions. Octagon is headquartered in Wayne, PA, with European headquarters in Berkhamsted, UK. Octagon’s EDC Operations are located in Mountain View, CA. For more information please visit www.octagonresearch.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
